<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002086</url>
  </required_header>
  <id_info>
    <org_study_id>052C</org_study_id>
    <secondary_id>03</secondary_id>
    <nct_id>NCT00002086</nct_id>
  </id_info>
  <brief_title>A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection</brief_title>
  <official_title>A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      Primary: To determine whether the combination of zidovudine/zalcitabine/interferon alfa-n1&#xD;
      (Retrovir/HIVID/Wellferon) can produce complete responses (i.e., CD4 counts return to &gt;= 800&#xD;
      cells/mm3 for more than 24 weeks) in patients with virus sensitive to all three agents. To&#xD;
      determine the antiviral effect of the combination therapies as evidenced by measures of&#xD;
      quantitative viral load performed at select study centers only.&#xD;
&#xD;
      Secondary: To determine the effectiveness of Retrovir/HIVID and Retrovir/HIVID/Wellferon in&#xD;
      maintaining or increasing CD4 counts and preventing disease progression as evidenced by the&#xD;
      development of an AIDS-defining indicator disease. To determine the effect of these regimens&#xD;
      on secondary measures of clinical status (e.g., performance score, weight change, and&#xD;
      secondary infections) and on measures of virologic activity such as serum p24 antigen. To&#xD;
      assess the safety and tolerance of these regimens.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>256</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zalcitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon alfa-n1</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection documented by licensed ELISA confirmed by Western blot; OR positive HIV&#xD;
             culture; OR positive HIV antigen; OR plasma viremia.&#xD;
&#xD;
          -  CD4 counts &gt;= 300 and &lt;= 500 cells/mm3 on two occasions within 30 days prior to study&#xD;
             entry.&#xD;
&#xD;
        Patients &lt; 18 years of age must have written consent of parent or guardian. The effects of&#xD;
        the combination therapy on infants or the developing fetus are unknown. Patients are&#xD;
        encouraged to utilize adequate contraception while enrolled in the study.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms and conditions are excluded:&#xD;
&#xD;
          -  Current AIDS-defining indicator disease, including opportunistic infections, AIDS&#xD;
             dementia, AIDS-wasting syndrome, and AIDS-associated malignancy.&#xD;
&#xD;
          -  Grade 2 or worse peripheral neuropathy.&#xD;
&#xD;
          -  Intolerance to Retrovir at 600 mg/day, HIVID at 2.25 mg/day, or any interferon-alfa&#xD;
             product at 3.0 MU/day.&#xD;
&#xD;
          -  Significant cardiac dysfunction (NYHA grade 3 or 4).&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Chemotherapeutic agents during the 76 weeks following study entry.&#xD;
&#xD;
          -  Cardiac glycosides, antiarrhythmics, or vasodilators.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of AIDS-defining indicator disease, including opportunistic infections, AIDS&#xD;
             dementia, AIDS-wasting syndrome, or AIDS-associated malignancy.&#xD;
&#xD;
          -  History of grade 2 or worse peripheral neuropathy.&#xD;
&#xD;
          -  History of intolerance to Retrovir at 600 mg/day, HIVID at 2.25 mg/day, or any&#xD;
             interferon-alfa product at 3.0 MU/day.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  More than 3 months of any prior antiretroviral therapy.&#xD;
&#xD;
          -  Cytotoxic chemotherapy within 4 weeks prior to study entry.&#xD;
&#xD;
          -  Immunomodulating agents such as systemic corticosteroids, IL-2, IFN-alfa, or IFN-beta&#xD;
             within 4 weeks prior to study entry.&#xD;
&#xD;
          -  Cardiac glycosides, antiarrhythmics, or vasodilators.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiation therapy within 4 weeks prior to study entry. Current alcohol or illicit drug&#xD;
             use that would interfere with patient compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ViRx Inc</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marin County Specialty Clinic</name>
      <address>
        <city>San Rafael</city>
        <state>California</state>
        <zip>94903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown Univ Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stratogen of South Florida</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Research Clinic / Indiana Univ Hosp</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Kansas School of Medicine</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Univ Hosp / Div of Infectious Diseases</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>452670560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portland Veterans Adm Med Ctr / Rsch &amp; Education Grp</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt School of Medicine</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Utah School of Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lavelle J, Haas D, Barry D, Mustafa N, Mciunnis R, Rooney J. Long-term safety and efficacy of initial triple combination therapy with ZDV, ddC and interferon alpha-n1 vs. ZDV and ddC in patients with CD4+ cell counts 300-500 cells/mm3. Conf Retroviruses Opportunistic Infect. 1996 Jan 28-Feb 1;3rd:107</citation>
  </reference>
  <verification_date>October 1993</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Zalcitabine</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>Interferon-alpha</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Zalcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

